Sirtuin 6 activating peptides and cosmetic or pharmaceutical composition containing them

A cosmetic composition comprising:

• a peptide comprising a peptide sequence of highly conserved regions of human Sirtuin (SIRT) proteins, of general formula (I):
• R1-(AA)n-X1—X2—X3—X4—X5—X6-(AA)p-R2
• in which,
• X1 is glycine or threonine or histidine,
• X2 is alanine or glutamine or glycine,
• X3 is glycine or asparagine or serine,
• X4 is valine or isoleucine or leucine,
• X5 is serine or aspartic acid or phenylalanine,
• X6 is alanine or glutamic acid or lysine, and
• when X1 is glycine then X2 is alanine and X3 is glycine,
• when X1 is threonine then X3 is asparagine,
• when X1 is histidine then X2 is glycine,
• AA is any amino acid and n and p are integers between 0 and 2,
• R1 is the primary amino function of the N-terminal amino acid, free or substituted by an acyl type group having either an alkyl chain from C1 to C30, saturated or unsaturated, an acetyl group, or an aromatic group chosen from among a benzoyl, tosyl or benzyloxycarbonyl type group, and
• R2 is the hydroxyl group of the carboxyl function of the C-terminal amino acid, free or substituted by a group chosen from among an alkyl chain from C1 to C30, or an NH2, NHY or NYY group with Y representing an alkyl chain from C1 to C4;
• wherein the peptide is one of the following sequences:
• (SEQ ID NO:
• 3)
• Leu-Val-Gly-Ala-Gly-Val-Ser-Ala-NH2
• (SEQ ID NO:
• 4)
• Gly-Ala-Gly-Val-Ser-Ala-Glu
• (SEQ ID NO:
• 5)
• Gly-Ala-Gly-Val-Ser-Ala-Glu-NH2, and
• a physiologically acceptable medium,
• said cosmetic composition for repairing Deoxyribonucleic acid (DNA) degradation, for improving telomere maintenance, or for increasing the expression of keratinocyte differentiation markers and promoting the expression of extracellular matrix proteins by skin fibroblasts.

A method for treating cutaneous signs of aging and photo aging on skin, the method comprising:

• topically applying, to skin to be treated, a composition comprising an effective quantity of a peptide comprising a peptide sequence of highly conserved regions of human Sirtuin (SIRT) proteins, of general formula (I):
• R1-(AA)n-X1—X2—X3—X4—X5—X6-(AA)p-R2
• in which,
• X1 is glycine or threonine or histidine,
• X2 is alanine or glutamine or glycine,
• X3 is glycine or asparagine or serine,
• X4 is valine or isoleucine or leucine,
• X5 is serine or aspartic acid or phenylalanine,
• X6 is alanine or glutamic acid or lysine, and
• when X1 is glycine then X2 is alanine and X3 is glycine,
• when X1 is threonine then X3 is asparagine,
• when X1 is histidine then X2 is glycine,
• AA is any amino acid and n and p are integers between 0 and 2,
• R1 is the primary amino function of the N-terminal amino acid, free or substituted by an acyl type group having either an alkyl chain from C1 to C30, saturated or unsaturated, an acetyl group, or an aromatic group chosen from among a benzoyl, tosyl or benzyloxycarbonyl type group, and
• R2 is the hydroxyl group of the carboxyl function of the C-terminal amino acid, free or substituted by a group chosen from among an alkyl chain from C1 to C30, or an NH2, NHY or NYY group with Y representing an alkyl chain from C1 to C4,
• wherein the peptide is one of the following sequences:
• (SEQ ID NO:
• 3)
• Leu-Val-Gly-Ala-Gly-Val-Ser-Ala-NH2
• (SEQ ID NO:
• 4)
• Gly-Ala-Gly-Val-Ser-Ala-Glu
• (SEQ ID NO:
• 5)
• Gly-Ala-Gly-Val-Ser-Ala-Glu-NH2.